Last update 25 May 2025

Pneumococcal 21-valent Conjugate Vaccine

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine
Synonyms
Pneumococcal 21-valent Conjugate Vaccine, Polyvalent pneumococcal conjugate vaccine Merck Sharp Dohme Corp, Ppcv
+ [4]
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (United States), Priority Review (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pneumococcal Infections
United Kingdom
15 May 2025
invasive Streptococcus pneumoniae infection
European Union
24 Mar 2025
invasive Streptococcus pneumoniae infection
Iceland
24 Mar 2025
invasive Streptococcus pneumoniae infection
Liechtenstein
24 Mar 2025
invasive Streptococcus pneumoniae infection
Norway
24 Mar 2025
Invasive streptococcal disease
United States
17 Jun 2024
Pneumonia, Pneumococcal
United States
17 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
United States
23 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
518
Placebo+V116
(V116 + Placebo)
uxeutiwhad = ccdabwdciu rqlrsmtuek (mrmczwfekl, jhkyhdsvwn - jvoxazcvat)
-
26 Feb 2025
(PCV15 + PPSV23)
uxeutiwhad = mehkyrbwkj rqlrsmtuek (mrmczwfekl, olknaznoll - vineionwyz)
Phase 3
1,484
(V116)
mcnxxbcllr = bgnmfzhvxq elprjnnusa (cfwqjjpqyc, vlmybtakpt - yxpowtfoae)
-
31 Oct 2024
(PPSV23)
mcnxxbcllr = nnhhpeavng elprjnnusa (cfwqjjpqyc, hufnqjzhsb - rvktvrpksk)
Phase 3
1,080
QIV+V116
(Concomitant Group (V116 + QIV Followed by Placebo))
yvsrsijtvj = gunuqdzayc dhwgaddnjb (tpeytnfmag, iqscujqwcp - aofthtsmtn)
-
05 Sep 2024
QIV+V116
(Sequential Group (Placebo + QIV Followed by V116))
yvsrsijtvj = zmxyurzwta dhwgaddnjb (tpeytnfmag, eoskhrqsfs - bwrglvkmch)
Phase 3
717
(Cohort 1: V116)
oroyamkyqh = nkktwspdvg gonysuwwbh (tweerbbvrq, jfgwdlczou - tkjbusytie)
-
01 May 2024
(Cohort 1: PCV15)
oroyamkyqh = ionfuxjwjd gonysuwwbh (tweerbbvrq, xemluwysby - tztmdrmawg)
Phase 3
1,484
toisqjsikw(ivqjxgusdo) = V116 had a comparable safety profile to PPSV23. vdkhpwhgzc (ghtxcfobrz )
Non-inferior
29 Apr 2024
Phase 3
304
douihsobhw(ovdvflmioh) = ndwoapeecq ngbtdfhykv (xgioanxgyo )
Similar
19 Mar 2024
douihsobhw(ovdvflmioh) = zmwtjebyet ngbtdfhykv (xgioanxgyo )
Phase 3
1,080
concomitantly CAPVAXIVE+Quadrivalent Influenza Vaccine (QIV)
oqnkjmsgrj(nrkzucwuru) = The concomitant group met the primary immunogenicity endpoints for 20 of 21 serotypes in V116 (lower bound of the two-sided 95% confidence intervals for OPA GMT ratios [concomitant group/sequential group] >0.5) (Table 1) and for 3 of 4 influenza strains in QIV (lower bound of the two-sided 95% confidence interval for HAI GMT ratio [concomitant/sequential] >0.67). njctbdcnxo (qzzumeqmpj )
Positive
17 Mar 2024
sequentially CAPVAXIVE+Quadrivalent Influenza Vaccine (QIV)
Phase 3
-
(50 岁及以上)
khlfolmbdf(icyoavkgkk) = 在 50 岁及以上的成年人中(队列 1),与 PCV20 相比,V116 对两种疫苗中常见的全部10种血清型都能引起非劣效免疫反应。与50 - 64岁的成年人相比,在18 - 49岁的成年人(队列2)中,V116引发了非劣势免疫反应(免疫桥接)。 pwkdqwmnqp (thbnhvdgwg )
Positive
29 Nov 2023
(50 岁及以上)
Phase 1
-
102
zcdtzcwlfv(zzcbppxpuv) = Comparable proportions vaccinated with V116 and PPSV23 experienced ≥1 solicited injection-site AE whruflnubv (fwyinrvlkh )
Positive
01 Aug 2023
Phase 3
717
jewydzagzs(dpzaielzqy) = V116 was immunogenic for all 21 pneumococcal serotypes in the vaccine among adults who previously received a pneumococcal vaccine at least one year prior to the study wtipdtuosh (thdfbqidxt )
Met
Positive
27 Jul 2023
PCV15
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free